Egetis Therapeutics AB could soon join the list of promising rare disease biotechs acquired by pharma firms now that the Swedish group has confirmed talks have been held with prospective buyers.
Sweden’s Egetis Catches The Eye Of Suitors
In Talks Over Possible Takeover
With an EU submission imminent for its MCT8 deficiency therapy Emcitate, Egetis is in talks with “certain external partners” about an acquisition.
